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Abstract
Background: Patterns of diagnosis and management for men diagnosed with prostate cancer in Queensland,
Australia, have not yet been systematically documented and so assumptions of equity are untested. This
longitudinal study investigates the association between prostate cancer diagnostic and treatment outcomes and
key area-level characteristics and individual-level demographic, clinical and psychosocial factors.
Methods/Design: A total of 1064 men diagnosed with prostate cancer between February 2005 and July 2007
were recruited through hospital-based urology outpatient clinics and private practices in the centres of Brisbane,
Townsville and Mackay (82% of those referred). Additional clinical and diagnostic information for all 6609 men
diagnosed with prostate cancer in Queensland during the study period was obtained via the population-based
Queensland Cancer Registry.
Respondent data are collected using telephone and self-administered questionnaires at pre-treatment and at 2
months, 6 months, 12 months, 24 months, 36 months, 48 months and 60 months post-treatment. Assessments
include demographics, medical history, patterns of care, disease and treatment characteristics together with out-
comes associated with prostate cancer, as well as information about quality of life and psychological adjustment.
Complementary detailed treatment information is abstracted from participants’ medical records held in hospitals
and private treatment facilities and collated with health service utilisation data obtained from Medicare Australia.
Information about the characteristics of geographical areas is being obtained from data custodians such as the
Australian Bureau of Statistics. Geo-coding and spatial technology will be used to calculate road travel distances
from patients’ residences to treatment centres. Analyses will be conducted using standard statistical methods along
with multilevel regression models including individual and area-level components.
Conclusions: Information about the diagnostic and treatment patterns of men diagnosed with prostate cancer is
crucial for rational planning and development of health delivery and supportive care services to ensure equitable
access to health services, regardless of geographical location and individual characteristics.
This study is a secondary outcome of the randomised controlled trial registered with the Australian New Zealand
Clinical Trials Registry (ACTRN12607000233426)
Background
Internationally, prostate cancer is the second most
common cancer diagnosed among men worldwide
(12% of all cancers) and the 6th most common cause
of cancer-related deaths [1]. Prostate cancer is particu-
larly prevalent in developed countries such as the
United States, Scandinavian countries, Canada and
Australia, with about a six-fold difference between
high-incidence and low-incidence countries[2]. Among
Australian males in 2010, prostate cancer is expected
to have the second highest cancer-related disease bur-
den, measured by disability-adjusted life years
(DALYs), behind lung cancer [3].
Based on autopsy studies, substantial proportions of
men have histological prostate cancer that doesn’t cause
symptoms or death [4,5]. Since the introduction of PSA
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testing, increasing numbers of these indolent prostate can-
cers are now being diagnosed [6]. As such, many of the
prostate cancers being diagnosed will have little impact on
a man’s health even in the absence of treatment [7] and
that treatment may in fact be harmful as it may carry sig-
nificant side effects with no potential benefit. However
many prostate cancers do have the potential to metastasise
and cause death. Worldwide, there were nearly 260,000
deaths caused by prostate cancer in 2008, with 53% of
these being in developed regions[8]. We have shown pre-
viously that a diagnosis of prostate cancer has greater
implications for men diagnosed at a young age, with these
men being more likely to die prematurely[9]. Unfortu-
nately it is not currently possible to differentiate the indo-
lent cancers from those that have the potential to
metastasise before biopsy, thus making the important deci-
sion of whether to be screened and subsequent treatment
decisions potentially complex and distressing.
For localised prostate cancer, potentially curative
treatment options include surgery through radical pros-
tatectomy and radiation therapy (external beam and bra-
chytherapy). While these surgical or radiation
treatments may increase the chance of cure, they are
associated with a significant risk of impotence, and less
commonly urinary incontinence and bowel problems.
The prevalence and type of side-effects vary for different
treatment types[10]. Another treatment option is active
surveillance, in which treatment is initially deferred,
then initiated if the disease progresses. This differs from
“watchful waiting” in which medical treatment is
reserved until symptoms become evident, thus poten-
tially missing the opportunity for cure. In contrast close
observation maintains the likelihood of cure by interven-
ing before symptoms present.
The contrasting initial results recently published from
two large-scale prostate cancer screening trials in the
United States [11] and Europe [12] highlight the com-
plexity of issues surrounding the provision of diagnostic
and treatment services for prostate cancer. In the pre-
sence of already high PSA testing, the United States
study suggested that organised PSA population screen-
ing programs are likely to result in over-diagnosis and
over-treatment with little reduction in mortality. Con-
versely, in Europe where the prevalence of asymptomatic
detection is low, there is greater potential for screening
programs to reduce the number of advanced prostate
cancers and deaths from prostate cancer. A sub-study
conducted in Göteborg, Sweden, a country with a low
prevalence of PSA testing (3%)[13] found that using an
intention to treat analysis PSA testing almost halved the
risk of death from prostate cancer. A major difference
between this study and its two larger international pre-
decessors is its more appropriate duration of follow-up
viz. 14 years.
Internationally, there is substantial evidence that
socio-demographic factors, such as age, ethnicity, loca-
tion of residence and income are associated with pros-
tate cancer outcomes extending from the likelihood of a
man having a PSA test to differences in prostate cancer
management [2,14-18]. In Australia [15] there has been
a statistically significant and increasing excess of pros-
tate cancer mortality among men in regional and rural
areas compared with those living in capital cities. This
mortality excess was accompanied by lower rates of
radical prostatectomy and PSA testing in rural and
regional Australia, and was in spite of lower incidence
rates of prostate cancer.
At present, the patterns of care for men in Queens-
land, Australia, are not documented in any systematic
way. For example, for men diagnosed with prostate can-
cer, we currently do not know which medical treatments
they receive, what factors are associated with different
choices, nor the morbidity and mortality risks associated
with these different treatments in their settings. Since
this information is needed for the planning and develop-
ment of health delivery and supportive care services and
to ensure equitable access to health services, this longi-
tudinal study of men diagnosed with prostate cancer in
Queensland was undertaken.
Study Aims
Utilising a longitudinal study design and recruiting men
immediately after their initial diagnosis, this study aims
to obtain information about their initial symptoms and
diagnosis, and then prospectively follow them during
subsequent management to identify their pathways to
care and subsequent outcomes. Specifically it aims to:
1. Document the current diagnostic and treatment
patterns for men with prostate cancer, in Queens-
land, Australia;
2. Investigate the determinants of area-level and
individual-level variation in diagnostic and treatment
pathways;
3. Investigate the determinants of area-level and
individual-level variation in clinical, psychosocial and
survival outcomes following treatment for prostate
cancer;
4. Identify inequalities in diagnostic and treatment
pathways, with a view to translating that information
into health policy and practice decision-making.
Methods/Design
Study Design
This is a descriptive, longitudinal epidemiological study,
in which is embedded a randomised controlled trial of a
decision support intervention for men with localised
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prostate cancer. The descriptive epidemiology compo-
nent is a secondary outcome of the randomised con-
trolled trial [19] and has been registered with the
Australian New Zealand Clinical Trials Registry (regis-
tration number ACTRN12607000233426).
Funding and Support
This project was awarded funding by the (Australia)
National Health and Medical Research Council (ID:
442301) and a Cancer Council Queensland Research
Grant. Cancer Council Queensland provided additional
funding for the maintenance of the GIS software.
Ethical Clearance
The full study, including documentation of the patterns
of diagnosis and treatment, has been approved by the
Queensland University of Technology Human Research
Ethics Committee, in addition to the ethics committees
of ten public hospitals in Queensland. The collection of
Medicare data has been approved by Medicare Australia
and access to data from the Queensland Cancer Registry
was approved by Queensland Health.
Setting
Men diagnosed with prostate cancer in Queensland (Aus-
tralia) between February 2005 and July 2007 (inclusive) are
eligible for this study. As the second largest area of the
Australian states and territories, Queensland has the third
highest population of any state (4.4 million in 2009) and is
the most decentralised [20]. Recruitment is centred on the
two major tertiary treatment centres for prostate cancer in
Queensland; the greater Brisbane and Townsville areas.
Study areas
Participants were ascertained through urology outpatient
clinics in the Greenslopes Private, Royal Brisbane, Mater
Adults, Princess Alexandra, Ipswich, QEII, Redlands,
and Redcliffe Hospitals in Brisbane (and surrounds) and
through the Townsville General Hospital and Mackay
Base Hospital. Private patients were ascertained through
the private practices of Urologists in Brisbane (and
surrounds), Townsville and Mackay.
Participants
Study cohort
All men newly diagnosed with prostate cancer in
Queensland between 1st February 2005 and 31st July
2007 were potentially eligible for the study. Urologists
referred eligible men to the study if they were newly diag-
nosed with prostate cancer irrespective of stage of dis-
ease. The following exclusion criteria were used: previous
diagnosis of prostate cancer; inability to read, write and
speak English; history of dementia, head injury or
psychiatric illness; and no regular access to a telephone.
In all, 1291 men were referred to the study, with
1064 men (82.4% of referrals) eligible and agreeing to
participate. Figure 1 shows the flowchart of ineligible/
excluded men, completeness of data collection and attri-
tion from the study between recruitment and 12 months
post-treatment.
Population cohort
Clinical and diagnostic information for all men diag-
nosed with prostate cancer in Queensland during the
study period (February 2005 to July 2007), whether or
not they are in the study cohort, was accessed via the
Queensland Cancer Registry. This population-based data
will enable a comparison of demographic, geographical,
clinical and diagnostic information between the study
cohort and men diagnosed with prostate cancer who did
not take part in the study (n = 5545).
Individual-level data
Telephone and self-administered questionnaires
Data collection for the study cohort is via telephone and
self-administered questionnaires and occurs at pre-treat-
ment and 2 months, 6 months, 12 months, 24 months,
36 months, 48 months and 60 months post-treatment.
These assessments include demographic information,
medical history, self-reported diagnostic and treatment
information together with outcomes associated with
prostate cancer, including information about quality of
life and psychological adjustment. The quality of life
and psychological measures used in this study are well-
established and validated and have been described pre-
viously[19].
Demographics the demographic information collected
at baseline includes date of birth, marital status, ethni-
city, education level, income, current employment status
and health insurance.
Medical history includes family history of cancer, family
history of prostate cancer, body mass index (BMI), other
chronic conditions and co-morbidities and smoking
status.
Self-reported diagnostic and treatment information
This self-reported information includes PSA level,
Gleason score, previous screening history, the diagnos-
tic examinations performed together with the date and
location of each examination, the reasons leading to
the initial diagnosis, reasons for delaying the diagnosis,
the type of treatment undertaken and the date and
location of each type of treatment and the public or
private status of the treating facility. Detailed self-
report diagnostic and treatment information is col-
lected on all participants up to 6 months after primary
treatment commenced. We will continue to collect
basic information on disease progression and subse-
quent treatments up to 60 months following primary
treatment.
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Figure 1 Flowchart of recruitment, participation, data collection and attrition from study.
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Medical Records
For the study cohort, detailed treatment information is
being abstracted from participants’ medical records held
in hospitals and private treatment facilities. This
includes details of diagnosis and post-treatment PSA
levels, TNM Staging, diagnostic examinations performed
and the dates and locations of these examinations, the
types of treatment and the treating doctors and their
facilities. Any information pertaining to further treat-
ments such as radiation therapy, androgen deprivation
therapy and other medications is being collected as rele-
vant. Detailed information from medical records is col-
lected from diagnosis to 12 months after primary
treatment was started.
Medicare Information
Study participants are being asked to sign an additional
consent form to facilitate access to their medical records
through Medicare Australia. Data relating to health ser-
vice utilisation including general practitioner and specia-
list services, prescription drug use (from the
Pharmaceutical Benefits Scheme), diagnostic and ima-
ging tests and procedures is being obtained. Information
requested from Medicare Australia will cover a 7 year
period starting from the 1st January 2005 for each study
participant.
Queensland Cancer Registry data collection
For the entire population cohort, information is
obtained from the Queensland Cancer Registry (QCR)
regarding the clinical details recorded for each prostate
cancer diagnosis. These details include the Gleason
score, the tumour volume, number of positive cores,
the extent of invasion (including extraprostatic exten-
sion, seminal vesicle invasion and vascular invasion),
and, when radical prostatectomy is performed and a
lymhadenectomy is also undertaken, the number of
positive lymph nodes. When available and relevant,
details are obtained from multiple pathology reports
sourced within the Queensland Cancer Registry includ-
ing transrectal ultrasound (TRUS), Transurethral
Resection of the Prostate (TURP), prostatectomy,
lymph node dissection and bone biopsy pathology
reports.
Information will also be gathered from the QCR on
date of diagnosis, place of usual residence at diagnosis,
age group at diagnosis, gender, country of birth, marital
status, occupation and Indigenous status. Although
there is evidence of some under-identification, the Indi-
genous identifier in Queensland is considered to have
good coverage [21].
Area-level information
The smallest geographical entity used for this analysis is
Collection Districts (CDs) which cover Queensland
without gaps or overlap. There were 7567 populated
CDs in Queensland in 2006, with a median population
of 497 (range: 3 to 2372). These CDs can then be col-
lapsed to form Statistical Local Areas (SLA) using a
deterministic (m:1) match between the CDs and the
SLAs.
These SLAs are often based on local government
administrative areas, with the local governments being
responsible for local and regional service provision and
infrastructure. In 2006 there were 478 SLAs in Queens-
land with a median population of 5810 (range: 7 to
77523). The SLA is also used as the standard geographi-
cal area definition by most relevant data providers, in
particular the Queensland Cancer Registry and Austra-
lian Bureau of Statistics. The use of geo-coding enables
us to match all area-level information to the 2006
Australian Standard Geographic Classification definition,
thus removing any impact of changes in these
geographic boundaries over time.
Remoteness
Remoteness of residence when diagnosed with breast
cancer was categorized using the ARIA+ classification
[22], which categorizes remoteness into Major City,
Inner Regional, Outer Regional, Remote and Very
Remote areas. The ARIA+ classification is a purely geo-
graphic measure that considers road distance measure-
ments from localities, and is a measure of accessibility
and remoteness.
Socioeconomic status
Area-level socioeconomic disadvantage is measured
using the Index of Relative Socioeconomic Disadvantage
(IRSD) calculated by the Australian Bureau of Statistics
[23]. The IRSD provides a general measure of disadvan-
tage, and considers factors such as low income, low edu-
cational attainment, high unemployment, jobs in
relatively unskilled occupations.
Census data
The Australian Bureau of Statistics conducts a popula-
tion Census every 5 years, with the latest available data
currently available for 2006. Information is available
down to CD level, and then can be aggregated up to
SLA level. Variables include occupation, household
income, number of vehicles per occupied private dwell-
ing, marital status, Indigenous status, labour force status
and highest educational qualification.
Details about occupation were collapsed into “Blue
Collar” (including tradespersons, plant and machine
operators and drivers, and labourers and related work-
ers), “White collar” (including clerks, salespersons and
personal service workers), “Professional” (including man-
agers and administrators, professionals and para-profes-
sional), “Not in workforce” (including retired, students,
unemployed and home duties), “Unknown” (no informa-
tion available). Similar occupation categories have been
used previously [24].
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Geocoding of street address information All address
details for study respondents, diagnosing and treating
doctors and treatment facilities are geo-coded using
commercial software designed to clean and convert
street address information into spatial (latitude and
longitude) coordinates. When full street address infor-
mation for a patient, doctor or treating facilities is not
available, the centroid of the SLA will be used instead.
Road travel distance calculations Distances between
patients, diagnostic centres, treatment facilities and
other medical centres will be calculated directly from
the geo-coded latitude and longitude points. Many stu-
dies assessing distance to treatment have calculated
straight line distances [25-31], however this method may
under-estimate travel times [29], illustrating the impor-
tance of using accurate road distance and travel time
information [25,27]. These road distances and times will
be calculated using commercial GIS software, combined
with street network analysis and display tools: and cus-
tom GIS applications to enable calculation of the closest
road travel distance between one location (such as
patient’s residence) and multiple locations (such as var-
ious treatment facilities).
Primary Outcome Measures Diagnostic pathway: a
description of events and time line from first noticing
symptoms or presenting to a medical practitioner to the
definitive diagnosis. This includes the diagnostic inter-
val, defined as the time between the initial doctor’s con-
sultation for reasons that led to the prostate cancer
diagnosis, and the date of definitive diagnosis.
Treatment pathway: a description of events and time
line from the definitive diagnosis to 6 months post the
commencement of primary treatment. This includes the
treatment interval, which is the time between the defini-
tive diagnosis and the commencement of primary treat-
ment for the prostate cancer.
Treatment details: a description of the type, duration
and frequency of all treatments received by the partici-
pant between diagnosis and 6 months after the com-
mencement of primary treatment. Primary treatment is
considered the first most invasive treatment undergone
by the participant and is generally radical prostatectomy
or radiation therapy (either external beam radiotherapy
or brachytherapy). For participants who chose watchful
waiting or active surveillance, date of treatment is con-
sidered as the date the treatment decision is made.
Statistical analysis
Statistical analyses for this study will reflect the sam-
pling design, the data collection process, and the
research objectives as stated previously. Due to the typi-
cally highly skewed distributions of time to diagnosis or
treatment, standard methods for transforming the time
intervals such as the geometric mean or comparing
median times, will be used in the analyses. Crude and
adjusted logistic and multinomial regression analyses of
dichotomous and ordinal outcomes respectively, will be
used to assess the contribution that independent factors
have on men’s choice of treatment. We will also investi-
gate the representativeness of the study cohort com-
pared to the rest of the men diagnosed with prostate
cancer by comparing the distributions of those clinical
and demographic variables collected from the Queens-
land Cancer Registry.
Previous studies looking at patterns of diagnosis and
treatment have focussed on the individual-level data, or
ecological studies. In order to appropriately investigate
whether the observed patterns are due to the character-
istics of the cancer patients themselves, or the character-
istics of the geographical areas in which the individuals
live, it is important to be able to quantify the variation
between areas in terms of their diagnostic and treatment
profiles. Thus using a multilevel analytical design we can
then determine whether the observed variation is due to
the clustering of individuals (i.e. a composition effect) or
the environmental characteristics of the areas (i.e. a con-
text effect).
We have previously described the advantages of incor-
porating a multilevel perspective [32]. We will use mul-
tilevel models to assess whether geographic remoteness
and area-level disadvantage were associated with pros-
tate cancer outcomes after controlling for individual-
level socio-demographic characteristics. These models
will be fitted using MLwiN version 2.15 (University of
Bristol, United Kingdom).
There will be three stages in the model building pro-
cess. The first is the null model that including indivi-
duals (level 1) nested in SLAs (level 2), there are no
individual- or area-level variables in the fixed part of
this model. If there is a significant SLA-level random
term (indicated using Wald chi-square) then this is evi-
dence supporting significant between-SLA variation in
the prostate cancer outcome. Second, the null model
will be extended by including individual-level factors
(patient characteristics, disease stage, co-morbidity, and
access to health care and treatment services) as fixed
effects. This will inform us as to how much of the area-
variation in prostate cancer outcomes is due to these
individual-level (compositional) factors, and also assess
the contribution of each individual-level factor. Thirdly,
the area-level measures such as geographic remoteness
and area socioeconomic disadvantage will be included in
the model as fixed effects, to quantify how much of the
area-variation in prostate cancer outcomes is due to
these factors (independent of individual-level factors).
Subsequent models will also consider the cross-level
interactions between the individual-level and area-level
factors.
Baade et al. BMC Cancer 2010, 10:452
http://www.biomedcentral.com/1471-2407/10/452
Page 6 of 8
Power calculations
Cohort sample sizes were initially determined in order
to calculate differences in binomial proportions between
two equally-sized subgroups. Assuming pooled variance,
two-sided Z-test at 5% significance level, subgroup sam-
ple sizes of n = 500 men achieve 80% power to detect at
least an absolute difference between the subgroup pro-
portions of 9%.
Power calculations for the variation between and
within area units (using Optimum Design software[33])
are based solely on the approximate number of clusters
(statistical local areas) and records per cluster. The
study cohort covers 270 area units (SLAs), with between
1 and 66 (mean 3.9, median = 2) respondents in each
unit. Assuming 270 clusters with an average of 4 records
per cluster and a baseline proportion of 50%, this gives
80% power at 0.05% significance to detect a difference
in proportions between two subgroups of 11%.
Discussion
Prostate cancer is a cause of significant morbidity and
mortality among Western populations, including Austra-
lia, and carries with it substantial individual and public
health burden. Currently, little is known about the diag-
nostic and treatment patterns of men diagnosed with
prostate cancer in this setting and the extent to which
men who are diagnosed with this cancer have equitable
access to different treatment options and follow up care.
This lack of knowledge means that health services policy
and planning strategies to manage this illness are to a
large extent unguided by evidence. The present study
will address this knowledge and evidence gap by investi-
gating the diagnostic and treatment patterns of men
diagnosed with prostate cancer in Queensland; assessing
the extent to which these patterns systematically vary;
and the area level and individual factors that contribute
to any variation. We propose that this will provide a
basis for advocacy for improvements in prostate cancer
care and men’s health in general.
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